ChitogenX Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHNXF research report →
Companywww.chitogenx.com
ChitogenX Inc. , an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration.
- CEO
- Pierre Laurin
- IPO
- 2020
- Employees
- 5
- HQ
- Kirkland, QC, CA
Price Chart
Valuation
- Market Cap
- $627.63K
- P/E
- -0.23
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -6.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.40%
- ROIC
- 127.91%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,554,000 · 75.06%
- EPS
- $-0.02 · 83.62%
- Op Income
- $-2,830,000
- FCF YoY
- 68.44%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -2.05
- Avg Volume
- 23.80K
Get TickerSpark's AI analysis on CHNXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CHNXF Coverage
We haven't published any research on CHNXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHNXF Report →